Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024 report and make more profitable business decisions.
Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets (thrombocytes) leading to an increased risk of blood clots. Over time, a subset of individuals with ET may progress to myelofibrosis, a condition where the bone marrow becomes fibrotic (scarred), leading to impaired production of blood cells. The symptoms of post-ET MF can vary widely and include fatigue, weakness, and shortness of breath due to anemia; enlargement of the spleen, leading to abdominal discomfort or pain; bone pain, especially in the ribs and back; easy bruising, bleeding, or prolonged bleeding time due to abnormal platelet function; and night sweats, weight loss, or fever.
The Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) drugs in development market research report provide comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 42 molecules, with 42 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncActuate Therapeutics Inc
Antengene Corp Ltd
Bristol-Myers Squibb Co
Cellenkos Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CTI BioPharma Corp
Disc Medicine Inc
Galecto Inc
Geron Corp
GSK plc
Hangzhou East China Pharmaceutical Group Co Ltd
Imago BioSciences Inc
Incyte Corp
IO Biotech Inc
iOnctura SA
Italfarmaco SpA
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Merck & Co Inc
MorphoSys AG
Novartis AG
NS Pharma Inc
Pharmaxis Ltd
Samus Therapeutics Inc
Sino Biopharmaceutical Ltd
Sumitomo Dainippon Pharma Oncology
Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Telios Pharma Inc
TG Therapeutics Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd